Abstract:Abstract Aims Atrial fibrillation (AF) is the most common cardiac arrhythmia closely associated with stroke, heart failure, and decreased quality of life. Excess adiposity has long been associated with increased cardiovascular disease and risk factor of AF. Methods Epicardial Adipose Tissue (EAT) is the fat depot located between the myocardium and the epicardium supplied by branches of the coronary arteries. By contrast, pericardial adipose tissue (PAT) is located externally and is supplied by non-coronary arteries. EAT fat thickness was first visualized by and measured with Transthoracic Two-dimensional (2D) Echocardiography because is visible as an echo free space between the outer wall of the myocardium and the visceral layer of the pericardium. Moreover, computed tomography (CT) has been used to measure EAT through accurate volumetric measurement. CMR imaging is instead considered the ‘gold standard’ modality for imaging adipose tissue.EAT function and morphology in normal conditions is protective but it function changes under pathological conditions.Lots of studies, infact, indicated higher pericardial fat volume was associated with a nearly 40% higher odds of prevalent AF, and the association remained significant even after adjustment for other AF risk factors including age, sex, myocardial infarction, heart failure, BMI, and other regional fat deposits. Infact, EAT volume is related to impaired diastolic function, elevated left ventricular mass, and enlarged left atrium. Moreover, a higher degree of EAT accumulation is often observed in patients with systematic inflammatory disease and oxidative stress, such as rheumatoid arthritis and psoriasis, compared with those without systematic inflammatory disease even after adjusting other risk factors. Free fatty acids can be transported from EAT to the myocardium and lead to electromechanical changes in atrial tissue: they separate cardiomyocytes and this situation result in conduction slowing, loss of side-to-side cell connections and myocardial disorganization that leads to conduction delay and re-entry. Results EAT is a modifiable cardiovascular risk factor and a potential novel therapeutic target owing to its responsiveness to drugs with pleiotropic effects such as GLP1R agonists (visceral fat reduction is one of the non-glycaemic effects of the GLP1R agonists), SGLT2 inhibitors (reduction of intramyocardial lipid content by increasing EAT lipolysis and ketone body oxidation) and statins (reduction of EAT thickness through modulation of peroxisome proliferator-activated receptors (PPARs)). Furthemore, suppression of AF after injecting botulinum toxin into EAT in patients with paroxysmal AF, both during postoperative cardiac surgery and catheter ablation of epicardial fat pad can also result in EAT reduction. Conclusion EAT is a measurable and modifiable cardiovascular risk factor that adds qualitative value to the stratification of cardiovascular risk. In the context of atrial fibrillation, EAT represents a new pathogenic substrate through the regional secretion of factors that induce fibrosis and neurohormonal disarray of the atrial myocytes. Genetic studies are also optional to uncover pathophysiological mechanism of EAT-AF interaction and clarify causal relationship. Finally, more efforts should be made to realize application of EAT quantification in risk evaluation and management for AF.

The Relationship between Epicardial Fat and Atrial Fibrillation Cannot Be Fully Explained by Left Atrial Fibrosis

Role of epicardial adipose tissue volume as predictor of atrial fibrillation recurrence

Is There an Association between Epicardial Adipose Tissue and Outcomes after Paroxysmal Atrial Fibrillation Catheter Ablation?

Epicardial adipose tissue volume is not an independent predictor of atrial fibrillation recurrence after catheter ablation

Epicardial adipose tissue is associated with left atrial volume and fibrosis in patients with atrial fibrillation

Epicardial adipose tissue volume assessed by cardiac CT as a predictor of atrial fibrillation recurrence following catheter ablation

The spatial overlap between left atrial epicardial adipose tissue and fibrosis is not associated to clinical stage of atrial fibrillation

The Relationship between Enhancing Left Atrial Adipose Tissue at CT and Recurrent Atrial Fibrillation.

Epicardial Adipose Tissue and Atrial Fibrillation Recurrence following Catheter Ablation: A Systematic Review and Meta-Analysis

Epicardial adipose tissue and its association with atrial fibrillation in middle-aged patients without overt heart disease

MRI-quantified left atrial epicardial adipose tissue predicts atrial fibrillation recurrence following catheter ablation

Epicardial Atrial Fat at Cardiac Magnetic Resonance Imaging and AF Recurrence after Transcatheter Ablation

The predictive value of left atrium epicardial adipose tissue on recurrence after catheter ablation in patients with different types of atrial fibrillation

The Correlation between Epicardial Adipose Tissue Thickness Measured by Echocardiography and P-Wave Dispersion and Atrial Fibrillation

Quantification of epicardial adipose tissue in patients undergoing hybrid ablation for atrial fibrillation

Quantitative Analysis of Quantity and Distribution of Epicardial Adipose Tissue Surrounding the Left Atrium in Patients with Atrial Fibrillation and Effect of Recurrence after Ablation.

Association between epicardial adipose tissue and recurrence of atrial fibrillation after ablation: a propensity score-matched analysis

Is Epicardial Adipose Tissue Associated with Atrial Fibrillation Following Cardiac Surgery? A Systematic Review and Meta-Analysis

Abstract 16865: Epicardial Adipose Tissue Density Predicts the Presence of Atrial Fibrillation and Its Recurrence After Catheter Ablation: Three-Dimensional Reconstructed Image Analysis

Redistribution of Adipose Tissue is Associated with Left Atrial Remodeling and Dysfunction in Patients with Atrial Fibrillation

700 EPICARDIAL ADIPOSE TISSUE AND ATRIAL FIBRILLATION, A REVIEW